130 related articles for article (PubMed ID: 30710305)
1. Serum S100B Levels in Melanoma.
Frauchiger AL; Dummer R; Mangana J
Methods Mol Biol; 2019; 1929():691-700. PubMed ID: 30710305
[TBL] [Abstract][Full Text] [Related]
2. Circulating melanoma exosomes as diagnostic and prognosis biomarkers.
Alegre E; Zubiri L; Perez-Gracia JL; González-Cao M; Soria L; Martín-Algarra S; González A
Clin Chim Acta; 2016 Feb; 454():28-32. PubMed ID: 26724367
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
4. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
5. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
6. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
Gebhardt C; Lichtenberger R; Utikal J
J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
[TBL] [Abstract][Full Text] [Related]
7. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
8. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
[TBL] [Abstract][Full Text] [Related]
10. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
[TBL] [Abstract][Full Text] [Related]
11. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
12. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
15. [Serum markers for melanoma].
Ugurel S
Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
[TBL] [Abstract][Full Text] [Related]
16. Clinical Use of the Calcium-Binding S100B Protein, a Biomarker for Head Injury.
Astrand R; Undén J
Methods Mol Biol; 2019; 1929():679-690. PubMed ID: 30710304
[TBL] [Abstract][Full Text] [Related]
17. Interrelationship of serum S100B and P53 in brain tumour patients.
Syeda T; Rizvi HA; Hadi SM; M Hashim AS; Khan MH
J Pak Med Assoc; 2016 Jun; 66(6):748-50. PubMed ID: 27339581
[TBL] [Abstract][Full Text] [Related]
18. Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.
Djukanovic D; Hofmann U; Sucker A; Schadendorf D
Br J Dermatol; 2001 Dec; 145(6):1030-1. PubMed ID: 11899133
[No Abstract] [Full Text] [Related]
19. S100B expression in breast cancer as a predictive marker for cancer metastasis.
Yen MC; Huang YC; Kan JY; Kuo PL; Hou MF; Hsu YL
Int J Oncol; 2018 Feb; 52(2):433-440. PubMed ID: 29345293
[TBL] [Abstract][Full Text] [Related]
20. [S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience].
Jäckel A; Deichmann M; Waldmann V; Bock M; Näher H
Hautarzt; 1999 Apr; 50(4):250-6. PubMed ID: 10354916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
